Recombinant factor VIIa in preterm neonates with prolonged prothrombin time

Blood Coagulation and Fibrinolysis

Volumn 14, Issue 1, 2003, Pages 117-120

  Greisen, Gorm ^a   Andreasen, Rinette B ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Baby; Coagulation; Deficiency; Haemorrhage; Immaturity; Vitamin K dependent factor

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; GESTATIONAL AGE; HEMOSTASIS; HUMAN; LUNG HEMORRHAGE; NEWBORN; PREMATURITY; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UMBILICAL CORD;

BLOOD COAGULATION DISORDERS; BLOOD TRANSFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VII; FEMALE; HUMANS; INFANT, NEWBORN; MALE; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PROTHROMBIN TIME; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 0037276728     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200301000-00021     Document Type: Article

References (11)

1. Andrew M. The relevance of developmental hemostasis to hemorrhagic disorders of newborns. Semin Perinatol 1997; 211:70-85.
2. Turner TL. Coagulation disorders. In: Rennie JM, Robertson NRC (editors): Textbook of neonatology. Edinburgh: Churchill Livingstone; 1999, pp. 795-805.
3. Northern Neonatal Nursing Initiative Trial Group. Randomised trial of prophylactic early fresh-frozen plasma or gelatin or glucose in preterm babies. Outcome at 2 years. Lancet 1996; 348:229-232.
4. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinol 1998; 9:119-128.
5. Bernstein DE, Jeffers L, Erhardsen E, Reddy KR, Glazer S, Squiban P, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113:1930-1937.
6. Eilersen E, Melsen T, Ingerslev J, Andreasen RB, Vilstrup H. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrobin time in patients with cirrhosis during bleeding from esophageal varices. Scand J Gastroenterol (in press).
7. Roberts HR. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinololysis 1998; 9 (Suppl 1):115-118.
8. Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, et al. Pharmacokinetics and pharmocodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55:638-648.
9. Rapaport SI. Coagulation problems in liver disease. Blood Coagul Fibrinolysis 2000; 11 (Suppl 1):S69-S74.
10. Duncan A, Benson L, Critz A, Abshire T. Neonatal coagulopathy treatment with rFVIIa [Abstract]. Pediatr Res 2001; 49:290A.
11. Boo NY, Wong NC, Zulkifli SS, Lye MS. Risk factors associated with umbilical vascular catheter-associated thrombosis in newborn infants. J Paediatr Child Health 1999; 35:460-465.